| Dermatitis, Atopic
Cibinqo vs Ebglyss
Side-by-side clinical, coverage, and cost comparison for dermatitis, atopic.Deep comparison between: Cibinqo vs Ebglyss with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsEbglyss has a higher rate of injection site reactions vs Cibinqo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ebglyss but not Cibinqo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cibinqo
Ebglyss
At A Glance
Oral
Once daily
JAK inhibitor
SC injection
Every 2-4 weeks
IL-13 antagonist
Indications
- Dermatitis, Atopic
- Dermatitis, Atopic
Dosing
Dermatitis, Atopic 100 mg orally once daily; may increase to 200 mg once daily for inadequate response. In moderate renal impairment or CYP2C19 poor metabolizers: 50 mg once daily, may increase to 100 mg once daily for inadequate response.
Dermatitis, Atopic 500 mg (two 250 mg injections) SC at Week 0 and Week 2, then 250 mg every 2 weeks until Week 16 or adequate clinical response; maintenance dose is 250 mg every 4 weeks SC.
Contraindications
- Patients taking antiplatelet therapies (except low-dose aspirin <=81 mg daily) during the first 3 months of treatment
- Prior serious hypersensitivity to lebrikizumab-lbkz or any excipient of EBGLYSS
Adverse Reactions
Most common (>=1%) Nasopharyngitis (8.7-12.4%), nausea (6.0-14.5%), headache (6.0-7.8%), herpes simplex (3.3-4.2%), increased blood creatine phosphokinase (2.3-2.9%), dizziness (1.8-2.9%), urinary tract infection (1.7-2.2%), fatigue (1.3-1.6%), acne (1.6-4.7%), vomiting (1.5-3.2%), impetigo (0.5-1.5%), oropharyngeal pain (1.0-1.4%), hypertension (0.8-1.2%), influenza (1.1-1.2%), gastroenteritis (1.1-1.3%), dermatitis contact (0.5-1.1%), abdominal pain upper (0.6-1.9%), abdominal discomfort (0.5-1.2%), herpes zoster (0.3-1.2%), thrombocytopenia (0-1.5%)
Serious Serious infections including herpes simplex, herpes zoster, and pneumonia (2.3 per 100 patient-years); thrombosis including pulmonary embolism and deep vein thrombosis; major adverse cardiovascular events; malignancy; retinal detachment
Most common (>=1%) conjunctivitis, injection site reactions, herpes zoster
Serious hypersensitivity, conjunctivitis, keratitis
Pharmacology
Abrocitinib is a Janus kinase (JAK) inhibitor that reversibly inhibits JAK1 by blocking the ATP binding site. It is selective for JAK1 over JAK2 (28-fold), JAK3 (>340-fold), and TYK2 (43-fold).
Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity to IL-13, inhibiting IL-13 signaling through the IL-4Ra/IL-13Ra1 receptor complex; IL-13 is a cytokine central to Type 2 inflammation in atopic dermatitis pathogenesis.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cibinqo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
Ebglyss
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (9/12)
UnitedHealthcare
Cibinqo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (4/8)
Ebglyss
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (8/8) · Qty limit (4/8)
Humana
Cibinqo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Ebglyss
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAssistance Fund: Atopic Dermatitis
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$25/momo
Ebglyss Savings Card - Non-covered benefitCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CibinqoView full Cibinqo profile
EbglyssView full Ebglyss profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.